CAR T-Cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights

As more experience with CAR T-cell approaches is examined, it is interesting to consider how both tumor-cell specific and microenvironment factors that define these highly aggressive subsets influence susceptibility to this approach.